<DOC>
	<DOCNO>NCT00055549</DOCNO>
	<brief_summary>This study examine dextromethorphan , drug alters reflexes larynx ( voice box ) , might change voice symptom people voice disorder due uncontrolled laryngeal muscle spasm . These include abductor spasmodic dysphonia ( breathy voice break ) , adductor spasmodic dysphonia ( vowel break ) , muscular tension dysphonia ( tight strain voice ) , vocal tremor ( tremulous voice ) . Dextromethorphan-one group drug call NMDA antagonists-has use year over-the-counter cough suppressant medicine . In animal study , drug block one reflex larynx may associate spasm laryngeal muscle . This study compare effect dextromethorphan , lorazepam ( valium-type drug ) , placebo ( inactive substance ) patient four type voice disorder describe . Patients spasmodic dysphonia , muscular tension dysphonia vocal tremor may eligible study . Individuals smoke use tobacco , vocal nodule polyp , history airway obstruction may participate . Candidates screen medical history physical examination , questionnaire , voice recording ( repeat sentence microphone ) , nasolaryngoscopy ( examination larynx tube advance nose ) . For nasolaryngoscopy , inside nose spray decongestant ( open nasal passage ) possibly local anesthetic . A small , flexible tube call nasolaryngoscope pass nose look larynx speech task , sing , whistle prolonged vowel . Participants admit NIH Clinical Center three visit , last afternoon one day late afternoon follow day . At visit , patient complete questionnaire , baseline speech recording , test sedation level . They take three pills-either dextromethorphan , lorazepam , placebo-one every 6 hour . Vital sign check every 6 hour level sedation waking hour monitor . One three hour take third pill , speech recording , questionnaire test sedation repeat check possible voice change . Patients give different pill visit .</brief_summary>
	<brief_title>Dextromethorphan Treat Patients With Voice Spasms</brief_title>
	<detailed_description>Studies spasmodic dysphonia ( SD ) increasingly point possibility central sensori-motor control disorder . Sensori-motor processing find abnormal adductor abductor spasmodic dysphonia base reflex conditioning study . These study demonstrate increased frequency R2 muscle response rapid pair presentation electrical stimulus superior laryngeal nerve spasmodic dysphonia . Thus , uncontrolled R2 response hypothesize basis uncontrolled muscle burst patient . Selective suppression late R2 laryngeal adductor responses N-methyl-D-Aspartate ( NMDA ) blockade cat demonstrate Ambalavanar et.al . In particular , dextromethorphan reduce frequency R2 responses 95 % 25 % ( P = 0.015 ) . Dextromethorphan widely use antitussive agent use 30 year . In double-blind randomized crossover design , 3 group patient receive randomly assign one 6 order cohort . They receive either dextromethorphan 8 mg/kg/d dose divide Q6 hour dose schedule 3 dos administer PO every 6 hour 3 dosage , 04 mg/kg/d lorazepam PO every 6 hour 3 dosage placebo administrate way Phase A . After minimum 1-week washout interval , patient give either medication placebo Phase B remain medication placebo Phase C. Our hypothesis dextromethorphan , NMDA receptor blocker , reduce voice break spasmodic dysphonia great degree lorazepam , similar sedate side effect , affect NMDA receptor different mechanism . On hand , patient idiopathic voice disorder , muscular tension dysphonia vocal tremor , hypothesize similar benefit dextromethorphan . During double-blind randomize cross-over study , three group include , 10 patient adductor abductor spasmodic dysphonia , 10 muscular tension dysphonia 10 vocal tremor . The result determine dextromethorphan potential treatment option patient adductor abductor SD .</detailed_description>
	<mesh_term>Voice Disorders</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients Spasmodic Dysphonia meet follow criterion : 1 . No structural abnormality affect larynx vocal fold nodule , polyp , carcinoma , cyst , contact ulcer , inflammation ( laryngitis ) . 2 . Symptoms adductor abductor spasmodic dysphonia present speech apparent rest , 3 . Symptoms adductor abductor spasmodic dysphonia less evident whisper , sing falsetto . 4 . Symptoms adductor abductor spasmodic dysphonia become worse prolonged speaking , practice anxiety . 5 . Reflexive emotional aspect voice function unaffected , cough laughter cry . Patients Muscular Tension Dysphonia meet follow criterion : 1 . Increased phonatory muscle tension paralaryngeal suprahyoid muscle palpation , 2 . Constant elevation larynx neck speech . 3 . A consistent hypertonic laryngeal posture phonation , either open posterior glottic chink arytenoid cartilages phonation , anteriorposterior squeeze ( pin hole posture ) ventricular hyperadduction . 4 . A normally appear larynx . Patients vocal tremor tremor isolate larynx without noticeable tremor head pharynx . Tremor vocal fold evident prolong vowel also noticeable larynx connect speech contain vowel . EXCLUSION CRITERIA : Subjects three group without : 1 . Cardiac , pulmonary , neurological , psychiatric speech hearing problem determine medical history examination physician EKG . Any patient history airway obstruction exclude study . 2 . Reduction range vocal fold movement nonspeech task whistle suggest either paralysis paresis , joint abnormality neoplasm . 3 . No smoker tobacco user include study . 4 . Exclude mucosal change vocal nodule polyp . 5 . Subjects history psychiatric disorder , care psychiatrist , medication treatment psychiatric disorder exclude study . Examples psychiatric disorder exclude : somatoform disorder , conversion disorder , currently treatment major depression , history schizophrenia bipolar disorder . However , history previous episode minor reactive depression would exclude person participation . 6 . Subjects take carbonic anhydrase inhibitor , cimetidine , hydrochlorthiazide , nicotine , quinidine , ranitidine , sodium calcium bicarbonate triamterene must either discontinue medication exclude study . 7 . Subjects grade 2 high hepatic renal dysfunction exclude study . 8 . Pregnant woman exclude study know study drug harmful fetus . If woman become pregnant study , remove .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 13, 2009</verification_date>
	<keyword>Dextromethorphan</keyword>
	<keyword>Sensorimotor Modulation</keyword>
	<keyword>Spasmodic Dysphonia</keyword>
	<keyword>Muscular Tension Dysphonia</keyword>
	<keyword>Voice Tremor</keyword>
	<keyword>Lorazepam</keyword>
	<keyword>Dysphonia</keyword>
	<keyword>Macular Tension Dysphonia</keyword>
</DOC>